A549 cell proliferation inhibited by RNAi mediated silencing of the Nrf2 gene

Bio-Medical Materials and Engineering

Volumn 24, Issue 6, 2014, Pages 3905-3916

  Bo, Zhang ^a,b   Chen, Xie ^a   Jing, Zhong ^a   Hanyin, Chen ^a,b   Hongying, Zhang ^a   Xiaoqin, Wang ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SHIHEZI UNIVERSITY   (China)

Author keywords

A549 cell; Cell transfection; Gene silence; Nrf2; Shikonin

Indexed keywords

ANTIOXIDANTS; BIOLOGICAL ORGANS; CELL PROLIFERATION; CELLS; CHEMOTHERAPY; CYTOLOGY; DETOXIFICATION; DISEASES; DRUG PRODUCTS; FREE RADICALS; PEPTIDES; POLYMERASE CHAIN REACTION; TRANSCRIPTION;

A549 CELLS; CELL TRANSFECTION; GENE SILENCE; NRF2; SHIKONIN;

MOLECULAR BIOLOGY;

ANTIOXIDANT; GLUTATHIONE; GLUTATHIONE DISULFIDE; MULTIDRUG RESISTANCE PROTEIN; REACTIVE OXYGEN METABOLITE; SHIKONIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NRF2; NFE2L2 PROTEIN, HUMAN;

A549 CELL LINE; ANTIPROLIFERATIVE ACTIVITY; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CELL VIABILITY ASSAY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NON SMALL CELL LUNG CANCER; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; GENETICS; LUNG TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; NF-E2-RELATED FACTOR 2; RNA INTERFERENCE; TRANSFECTION;

EID: 84907279714     PISSN: 09592989     EISSN: 18783619     Source Type: Journal    
DOI: 10.3233/BME-141222     Document Type: Conference Paper

References (56)

1. A. Nadkar, C. Pungaliya, K. Drake, E. Zajac, S.S Singhal and S. Awasthi, Therapeutic resistance in lung cancer, Expert Opin. Drug Metab. Toxicol. 2 (2006), 753-777.
2. A. Singh, S. Boldin-Adamsky, R.K. Thimmulappa, S.K. Rath, H. Ashush, J. Coulter et al., RNAi mediated silencing of Nrf2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy, Cancer Res. 68 (2008), 7975-7984.
3. Y. Soini, U. Napankangas, K. Jarvinen, R. Kaarteenaho-Wiik, P. Paakko and V.L. Kinnula, Expression of gammaglutamyl cysteine synthetase in nonsmall cell lung carcinoma, Cancer 92 (2001), 2911-2919.
4. K.D. Tew, Glutathione-associated enzymes in anticancer drug resistance, Cancer Res. 54 (1994), 4313-4320.
5. P. Yang, J.O. Ebbert, Z. Sun and R.M. Weinshilboum, Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: A review, J. Clin. Oncol. 24 (2006), 1761-1769.
6. D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, H. Pelicano et al., Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate, Cancer Cell 10 (2006), 241-252.
7. A. Kobayashi, M.I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, T. Chiba et al., Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2, Mol. Cell Biol. 24 (2004), 7130-7139.
8. D.D. Zhang, S.C. Lo, J.V. Cross, D.J. Templeton and M. Hannink, Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex, Mol. Cell Biol. 24 (2004), 10941-10953.
9. T.W. Kensler, N. Wakabayashi and S. Biswal, Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway, Annu. Rev. Pharmacol. Toxicol. 47 (2007), 89-116.
10. A.Hayashi, H. Suzuki, K. Itoh, M. Yamamoto and Y. Sugiyama, Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts, Biochem. Biophys. Res. Commun. 310 (2003), 824-829.
11. T. Nguyen, P.J. Sherratt and C.B. Pickett, Regulatory mechanisms controlling gene expression mediated by the antioxidant response element, Annu. Rev. Pharmacol. Toxicol. 43 (2003), 233-260.
12. V. Vollrath, A.M. Wielandt, M. Iruretagoyena and J. Chianale, Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene, Biochem. J. 395 (2006), 599-609.
13. Y.J. Kim, J.Y. Ahn, P. Liang, C. Ip, Y. Zhang and Y.M. Park, Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology, Cancer Res. 67 (2007), 546-554.
14. T.D. Lee, H. Yang, J. Whang and S.C. Lu, Cloning and characterization of the human glutathione synthetase 5'-flanking region, Biochem. J. 390 (2005), 521-528.
15. T. Rangasamy, C.Y. Cho, R.K. Thimmulappa, L. Zhen, S.S. Srisuma, T.W. Kensler, M. Yamamoto et al., Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice, J. Clin. Invest. 114 (2004), 1248-1259.
16. T. Rangasamy, J. Guo, W.A. Mitzner, J. Roman, A. Singh, A.D. Fryer et al., Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice, J. Exp. Med. 202 (2005), 47-59.
17. R.K. Thimmulappa, C. Scollick, K. Traore, M. Yates, M.A. Trush, K.T. Liby et al., Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide, Biochem. Biophys. Res. Commun. 351 (2006), 883-889.
18. K.U. Kotlo, F. Yehiely, E. Efimova, H. Harasty, B. Hesabi, K. Shchors et al., Nrf2 is an inhibitor of the Fas pathway as identified by Achilles' Heel Method, a New function-based approach to gene identification in human cells, Oncogene 22 (2003), 797-806.
19. N. Morito, K. Yoh, K. Itoh, A. Hirayama, A. Koyama, M. Yamamoto et al., Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels, Oncogene 22 (2003), 9275-9281.
20. H. Kanzaki, F. Shinohara, M. Kajiya and T. Kodama, The Keap1/Nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling, J. Biol. Chem. 288 (2013), 23009-23020.
21. D. Hanahan, DNA cloning, D.M. Glover, ed., ORL Press, Oxford, Washington DC, 1985, vol. 1, pp. 109-135.
22. G. Frampton, M. Coufal, H. Li, J. Ramirez and S. DeMorrow, Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling, Exp. Cell Res. 316 (2010), 1465-1478.
23. L. Huang, J.C. Ramirez, G.A. Frampton, L.E. Golden, M.A. Quinn, H.Y. Pae et al., Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor, Lab Invest. 91 (2010), 1007-1017.
24. S. DeMorrow, H. Francis, E. Gaudio, J. Venter, A. Franchitto, S. Kopriva et al., The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway, Am. J. Physiol. Gastrointest. Liver Physiol. 295 (2008), 1150-1158.
25. N. Wang, L.W. Wang, B.D. Gou, T.L. Zhang and K. Wang, Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells, Cell Biol. Int. 32 (2008), 1497-1505.
26. S. Caprodossi, M. Pedinotti, C. Amantini, G. Santoni, S. Minucci, P.G. Pelicci et al., Differentiation response of acute promyelocytic leukemia cells and PML/RAR? leukemogenic activity studies by real-time RT-PCR, Mol. Biotechnol. 30 (2005), 231-238.
27. T.W. Fischer, M.A. Zmijewski, B. Zbytek, T.W. Sweatman, R.M. Slominski, J. Wortsman et al., Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines, Int. J. Oncol. 29 (2006), 665-672.
28. H.R. Lee, J.M. Cho, D.H. Shin, C.S. Yong, H.G. Choi, N. Wakabayashi et al., Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation, Mol. Cell Biochem. 318 (2008), 23-31.
29. M.G. Baigi, L. Brault, A. Nuesque, M. Beley, R.E. Hilali, F. Ga.e et al., Apoptosis/necrosis switch in two different cancer cell lines: Influence of benzoquinone and hydrogen peroxide-induced oxidative stress intensity, and glutathione, Toxicol. in Vitro. 22 (2008), 1547-1554.
30. T. Amalraj, R. Jessica, K.K. Naveen, W.F. James and A. Sudhakar, Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor mediated cancer cell invasion, J. Biol. Chem. 28 (2011), 31-35.
31. D. Gao, M. Hiromura, H. Yasui and H. Sakurai, Direct reaction between shikonin and thiols induces apoptosis in HL60 cells, Biol. Pharm. Bull. 25 (2002), 827-832.
32. H. Wang, C. Wu, S. Wan, H. Zhang, S. Zhou and G. Liu, Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin 1 expression and the ERK1/2 signaling pathway, Toxicology 308 (2013), 104-112.
33. B. Padmanabhan, K.I. Tong, T. Ohta, Y. Nakamura, M. Scharlock, M. Ohtsuji et al., Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer, Mol. Cell 21 (2006), 689-700.
34. T. Sjoblom, S. Jones, L.D. Wood, D.W. Parsons, J. Lin, T.D. Barber et al., The consensus coding sequences of human breast and colorectal cancers, Science 314 (2006), 268-274.
35. T. Kurosu, T. Fukuda, T. Miki and O. Miura, BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells, Oncogene 22 (2003), 4459-4468.
36. B. Zhang, N. Chen, H. Chen, Z. Wang and Q. Zheng, The critical role of redox homeostasis in Shikonin-induced HL-60 cell differentiation via unique modulation of the Nrf2/ARE Pathway, Oxid. Med. Cell Longev. 2012 (2012), 781516.
37. W. Han, J. Xie, L. Li, Z. Liu and X. Hu, Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis, Apoptosis 14 (2009), 674-686.
38. W. Han, J. Xie, Y. Fang, Z. Wang and H. Pan, Nec-1 Enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2, Int. J. Mol. Sci. 13 (2012), 7212-7225.
39. S.M. Krance, P.C. Keng, J.P. Palis and N. Ballatori, Transient glutathione depletion determines terminal differentiation in HL-60 cells, Oxid. Med. Cell Longev. 3 (2010), 53-60.
40. I. Bobilev, V. Novik, I. Levi, O. Shpilberg, J. Levy, Y. Sharoni et al., The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells, Cancer Biol. Ther. 11 (2011), 317-329.
41. F.Q. Schafer and G.R. Buettner, Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple, Free Radic. Biol. Med. 30 (2001), 1191-1212.
42. A.T. Dinkova-Kostova and P. Talalay, NAD (P) H: quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector, Arch. Biochem. Biophys. 501 (2010), 116-123.
43. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji et al., Loss of keap1 function activates Nrf2 and provides advantages for lung cancer cell growth, Cancer Res. 68 (2008), 1303-1309.
44. D.T. Dickey, Y.J. Wu, L.L. Muldoon and E.A. Neuwelt, Protection against cisplatin-induced toxicities by Nacetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels, J. Pharmacol. Exp. Ther. 314 (2005), 1052-1058.
45. M.A. Fuertes, J. Castilla, C. Alonso and J.M. Perez, Novel concepts in the development of platinum antitumor drugs, Curr. Med. Chem. Anticancer Agents 2 (2002), 539-551.
46. E.A. Neuwelt, M.A. Pagel, B.P. Hasler, T.G. Deloughery and L.L. Muldoon, Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat Model, Cancer Res. 61 (2001), 7868-7874.
47. H. Masuda, T. Tanaka and U. Takahama, Cisplatin generates superoxide anion by interaction with DNA in a cell-free system, Biochem. Biophys. Res. Commun. 203 (1994), 1175-1180.
48. D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, H. Pelicano et al., Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate, Cancer Cell 10 (2006), 241-252.
49. S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi et al., Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer, Clin. Cancer Res. 15 (2009), 3423-3432.
50. T. Jiang, N. Chen, F. Zhao, X.J. Wang, B. Kong, W. Zheng et al., High levels of Nrf2 determine chemoresistance in type II endometrial cancer, Cancer Res. 70 (2010), 5486-5496.
51. G.S. Shim, S. Manandhar, D.H. Shin, T.H. Kim and M.K. Kwak, Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway, Free Radic. Biol. 47 (2010), 1619-1631.
52. K. Zhang, E.B. Yang, K.P. Wong and P. Mack, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin, Int. J. Oncol. 14 (1999), 861-867.
53. P. Yang, J.O. Ebbert, Z. Sun and R.M. Weinshilboum, Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review, J. Clin. Oncol. 24 (2006), 1761-1769.
54. V.P. Papageorgiou, A.N. Assimopoulou, E.A. Couladouros, D. Hepworth and K.C. Nicolaou, The chemistry and biology of alkannin, shikonin, and related naphthazarin natural products, Angew. Chem. Int. Ed. 38 (1999), 270-301.
55. X. Mao, C.R. Yu, W.H. Li and W.X. Li, Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells, Cell Res. 18 (2008), 879-888.
56. Y.B. Ji, C.F. Ji and L. Yue, Human gastric cancer cell line SGC-7901 apoptosis induced by SFPS-B2 via a mitochondrial-mediated pathway, Biomed. Mater. Eng. 24 (2014), 130914.